{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:44:20Z","timestamp":1792496660298,"version":"4.5.0"},"reference-count":34,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2023\/08810-3"],"award-info":[{"award-number":["2023\/08810-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2023\/08810-3"],"award-info":[{"award-number":["2023\/08810-3"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["#88887.687389\/2022-00"],"award-info":[{"award-number":["#88887.687389\/2022-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"award":["#88887.687389\/2022-00"],"award-info":[{"award-number":["#88887.687389\/2022-00"]}],"id":[{"id":"https:\/\/ror.org\/016e3ca54","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE); it is associated with increased morbidity and mortality, underscoring the need for new diagnostic markers and therapeutic strategies. In this context, the exostosin 1 (EXT1)\/exostosin 2 (EXT2) heterodimer has emerged as a novel antigen in membranous nephropathy associated with SLE. This study evaluated EXT1 prevalence in renal biopsies from patients with lupus membranous nephropathy (LMN) and compared clinical, laboratory, and histopathological characteristics on diagnosis and renal outcomes. Methods: This retrospective study included 97 LMN patients whose renal biopsy underwent immunohistochemistry (IHC) for EXT1. EXT1-positive and EXT1-negative groups were compared using descriptive analyses and repeated measures models. Results: EXT1 positivity was observed in 35% of the cohort, and is more frequent in pure LMN (40%) than in cases with a proliferative component (32%). Regarding SLE diagnostic criteria, EXT1-positive patients showed a higher frequency of antiphospholipid antibodies, although data were available for only a subset of patients. This group also exhibited lower serum creatinine levels, but without statistical significance. EXT1-negative patients more frequently received cyclophosphamide as induction therapy (57.6% vs. 34.5%; p = 0.041). No differences in clinical outcomes were observed during follow-up. Conclusions: EXT1 prevalence was consistent with the literature, reinforcing the epidemiological reproducibility of this marker. EXT1-positive and EXT1-negative groups did not differ regarding clinical presentation, disease progression, and renal outcomes, heightening the need for prospective studies to further elucidate the diagnostic and prognostic role of EXT1 in LMN.<\/jats:p>","DOI":"10.3390\/diagnostics16111591","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:30:33Z","timestamp":1779669033000},"page":"1591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of Exostosin 1 in Lupus Nephritis: Prevalence, Clinico\u2013Pathologic and Renal Outcome Correlations"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8502-1318","authenticated-orcid":false,"given":"Luiza Liza de","family":"Assis","sequence":"first","affiliation":[{"name":"Division of Nephrology, Hospital das Clinicas, University of Sao Paulo School of Medicine, Sao Paulo 05401-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-816X","authenticated-orcid":false,"given":"Denise Maria Avancini Costa","family":"Malheiros","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Sao Paulo School of Medicine, Sao Paulo 05401-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirce Maria","family":"Zanetta","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Sao Paulo School of Public Health, Sao Paulo 05401-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-0063","authenticated-orcid":false,"given":"Luis","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hospital das Clinicas, University of Sao Paulo School of Medicine, Sao Paulo 05401-010, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41598-022-07037-2","article-title":"Prevalence of neural epidermal growth factor-like 1- and exostosin 1\/exostosin 2-associated membranous nephropathy: A single-center retrospective study in Japan","volume":"12","author":"Iwakura","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2020.04.013","article-title":"Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study","volume":"76","author":"Hanset","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/Exostosin 2-Associated Membranous Nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","first-page":"e43619","article-title":"A Case of Pla2r and Exostosin 1 Positive Membranous Nephropathy\u2014The Diagnostic and Therapeutic Dilemma","volume":"15","author":"Sivagnanam","year":"2023","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41581-025-00980-z","article-title":"Antigens in membranous nephropathy: Discovery and clinical implications","volume":"21","author":"Sethi","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: From models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes","volume":"32","author":"Ravindran","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40620-023-01779-6","article-title":"Distribution spectrum and clinical significance of glomerular exostosin (EXT1) deposits in PLA2R-positive membranous nephropathy","volume":"37","author":"Liu","year":"2024","journal-title":"J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: Proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.ekir.2021.04.025","article-title":"The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets with Different Outcomes","volume":"6","author":"Tuffet","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2215\/CJN.00350122","article-title":"Glomerular Exostosin as a Subtype and Activity Marker of Class 5 Lupus Nephritis","volume":"17","author":"Wang","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/ndt\/gfac058","article-title":"EXT1 and NCAM1-associated membranous lupus nephritis in a cohort of patients undergoing repeat kidney biopsies","volume":"38","author":"Miller","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ekir.2024.01.008","article-title":"Glomerular Exostosin-Positivity is Associated with Disease Activity and Outcomes in Patients with Membranous Lupus Nephritis","volume":"9","author":"Xia","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00428-025-04157-8","article-title":"Repeat biopsies in membranous lupus nephritis in the era of target antigen identification","volume":"487","author":"Bernhard","year":"2025","journal-title":"Virchows Arch."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10067-024-07043-x","article-title":"Exostosin-1\/exostosin-2 expression and favorable kidney outcomes in lupus nephritis: A retrospective cohort study","volume":"43","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e001051","DOI":"10.1136\/lupus-2023-001051","article-title":"Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy","volume":"10","author":"Ye","year":"2023","journal-title":"Lupus Sci. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00428-021-03164-9","article-title":"Immunopathological analysis of the expression of glomerular exostosin 1 and exostosin 2 in Japanese patients with lupus nephritis","volume":"479","author":"Wada","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ndt\/gfv289","article-title":"Defining end-stage renal disease in clinical trials: A framework for adjudication","volume":"31","author":"Agarwal","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111991","DOI":"10.1016\/j.celrep.2023.111991","article-title":"Glycosyltransferase Extl1 promotes CCR7-mediated dendritic cell migration to restrain infection and autoimmunity","volume":"42","author":"Liu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ki.2008.260","article-title":"Glomerular filtration: The charge debate charges ahead","volume":"74","author":"Miner","year":"2008","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Buijsers, B., Garsen, M., de Graaf, M., Bebber, M.B.-V., Guo, C., Li, X., and van der Vlag, J. (2023). Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1098184"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/978-3-030-34521-1_26","article-title":"Heparanase in Kidney Disease","volume":"1221","author":"Buijsers","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"gfae069-1240-1267","DOI":"10.1093\/ndt\/gfae069.1240","article-title":"Exostosin 1-and 2-positive membranous nephropathy in Chinese patients","volume":"39","author":"Wang","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.matbio.2016.09.002","article-title":"Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation","volume":"57\u201358","author":"Borza","year":"2017","journal-title":"Matrix Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.bbagen.2019.02.009","article-title":"Heparan sulfate in chronic kidney diseases: Exploring the role of 3-O-sulfation","volume":"1863","author":"Ferreras","year":"2019","journal-title":"Biochim. Et Biophys. Acta\u2014Gen. Subj."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1523-1755.2005.00062.x","article-title":"Heparanase activity is dysregulated in children with steroid-sensitive nephrotic syndrome","volume":"67","author":"Holt","year":"2005","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2337\/db11-1024","article-title":"Heparanase is essential for the development of diabetic nephropathy in mice","volume":"61","author":"Gil","year":"2012","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1681\/ASN.2015091070","article-title":"Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular Glycocalyx","volume":"27","author":"Garsen","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1681\/ASN.2007080842","article-title":"Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation","volume":"19","author":"Roberts","year":"2008","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:34:21Z","timestamp":1792496061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16111591"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16111591","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}